Volume 24, Number 10—October 2018
Research
Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
Table 4
Characteristic |
Beta coefficient |
SE |
p value |
---|---|---|---|
Months on VDOT (per month) |
0.008 |
0.003 |
0.01 |
Country of birth (referent: other) | |||
Mexico | −0.095 | 0.022 | <0.001 |
United States |
−0.048 |
0.022 |
0.03 |
Perceived ease or difficulty of VDOT (referent: very easy) | |||
Somewhat easy | −0.003 | 0.024 | 0.90 |
Somewhat or very difficult |
−0.130 |
0.042 |
0.002 |
Took medications while away from home (referent: never or rarely) | |||
Less than half or half the time | −0.004 | 0.020 | 0.83 |
Most of the time or always |
−0.049 |
0.021 |
0.02 |
Had problems using the VDOT application (referent: never) | |||
Rarely | −0.001 | 0.018 | 0.97 |
Less than half the time | −0.040 | 0.029 | 0.16 |
More than half the time | −0.220 | 0.041 | <0.001 |
*FEDO, fraction of expected doses observed = number of complete doses observed through VDOT divided by the number of doses expected; VDOT, video directly observed therapy.
Page created: September 16, 2018
Page updated: September 16, 2018
Page reviewed: September 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.